Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Editorial Volume 5 Issue 6

HDAC11 Enzyme: Multifaceted Roles and New Avenues in Cancer Therapy

Vasundhara Sharma*

Department of Leukemia, Princess Margaret Cancer Center Toronto Canada

*Corresponding Author: Vasundhara Sharma, Department of Leukemia, Princess Margaret Cancer Center Toronto Canada.

Received: April 25, 2021; Published: May 01, 2020

  Histone deacetylases (HDACs) are enzymatically super-active in various malignancies, deacetylating lysine (K) moieties of amino acids, and altering the functional properties of a plethora of histone and non-histone proteins. Histone deacetylase 11 (HDAC11), a novel class IV HDAC, is a newly discovered HDAC, regulating multiple physiological programs in a wide variety of normal tissues and cancer cells. Enzymatically, it is a modest deacetylase as well as a deacylase of target proteins. Functionally, genetic ablation of HDAC11 is not lethal in murine models with no major implications on immune cell maturation or steady state hematopoiesis making it a potential therapeutic target in malignancies of hematopoietic stem and progenitor cells (HSPCs). Within various immune cell compartments, the regulatory role of HDAC11 is most prominent in antigen presenting cells (APCs) as a negative regulator of Interleukin 10 (IL-10) at transcriptional level. Also, the loss of HDAC11 is associated to increase in immunosuppressive properties of myeloid derived stem cells (MDSCs) suggestibly due to increase in expression of immunosuppressive molecules via increased transcription of C/EBPβ. Current studies designate HDAC11 as a sentinel molecule to maintain immunological homeostasis in naïve immune cells and also pose as a therapeutic target in context of stress activated immunity. Interestingly, rapidly increasing evidences show HDAC11 as a potential target in metabolic disorders too. Depletion of HDAC11 is shown to improve the metabolic health of murine models through transcriptional control of genes of thermogenesis. Also, in context of tumorigenic cells, a direct regulation of metabolic pathways like glycolysis and fatty acid utilization is amongst the top targets of HDAC11. Altogether, HDAC11 is an identified vulnerability with various physiological roles involved in multiple aspects of tumor biology. Further investigations at mechanistic level are needed to know long term therapeutic potentials of HDAC11.

References

Citation

Citation: Vasundhara Sharma. “HDAC11 Enzyme: Multifaceted Roles and New Avenues in Cancer Therapy". Acta Scientific Medical Sciences 5.6 (2021): 01.

Copyright

Copyright: © 2021 Vasundhara Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US